EA
BDTX icon

Emerald Advisers’s Black Diamond Therapeutics BDTX Stock Holding History

Emerald Advisers’s Portfolio BDTX Stock Details BDTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-2,643
Closed -$80K – 292
2020
Q3 		$80K Sell
2,643
-114,307
-98% -$3.48M ﹤0.01% 246
2020
Q2 		$4.93M Buy
116,950
+2,460
+2% +$90.5K 0.21% 110
2020
Q1 		$2.86M Buy
+114,490
New +$3.48M 0.17% 112

Other funds holding BDTX

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Emerald Advisers's BDTX Position: Q4 2020 in Review

Emerald Advisers sold out of Black Diamond Therapeutics (BDTX) in Q4 2020, closing a stake of 2,643 shares — an estimated $80K sold.

Emerald Advisers first reported a position in BDTX in Q1 2020 and held it in 3 quarters. The position peaked at $4.93M in Q2 2020. 109 funds tracked by Wall St. Rank hold BDTX as of Q4 2020.

  • Emerald Advisers reported no remaining Black Diamond Therapeutics position as of Q4 2020 after selling out during the quarter.
  • Emerald Advisers sold 2,643 Black Diamond Therapeutics shares in Q4 2020, an estimated $80K.
  • Emerald Advisers first reported a position in Black Diamond Therapeutics in Q1 2020 and held it in 3 quarters.
  • Emerald Advisers's Black Diamond Therapeutics position peaked at $4.93M in Q2 2020.
  • 109 funds tracked by Wall St. Rank held Black Diamond Therapeutics as of Q4 2020.

Based on Emerald Advisers's 13F filing for Q4 2020, filed 29 Jan 2021.